NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Alpha Natural (ANR) was upgraded at Brean Murray from Hold to Buy. Valuation call, based on a $15 price target, Brean Murray said.
Avon (AVP) was downgraded at UBS to Sell from Neutral. $13 price target. Remain cautious after selloff, UBS said.Boeing (BA) was upgraded at Argusto to Buy from Hold. $85 price target. Company will benefit from higher commercial flight demand, and airlines are looking to replace aging fleets, Argusto said. Bank of America (BAC) was downgraded at JMP Securities from Market Perform to Underperform. $5.50 price target. Expect a more strict Volcker rule to be passed, JMP said. Charles River Laboratories International (CRL) was downgraded to Hold at TheStreet Ratings. Citigroup (C - Get Report) was downgraded at JMP Securities to Underperform from Market Perform. Expect a divided Washington to be a headwind for financial stocks, JMP said. $23 price target. First Horizon (FHN) was upgraded at Guggenheim to Buy. Company can continue to buy back excess capital, Guggenheim said. $10 price target. First Niagara (FNFG) numbers were cut at Guggenheim. Shares are now seen reaching $9. Estimates were also reduced, given lower yields and high exposure to securities and mortgages, Guggenheim said. Neutral rating. Group 1 Automotive (GPI) was upgraded at Sterne Agee from Neutral to Buy. Valuation call, based on a $65 price target, Sterne Agee said. Goldman Sachs (GS - Get Report) was downgraded at JMP Securities from Outperform to Underperform. $77 price target. See more downside potential for the industry, which is facing multiple headwinds, JMP said. JP Morgan (JPM - Get Report) was downgraded at JMP Securities from Market Perform to Underperform. $28 price target. Troubles in Europe will continue to weigh on the industry, JMP Securities said. Manpower Group (MAN) was downgraded to Hold at TheStreet Ratings. Morgan Stanley (MS - Get Report) was downgraded at JMP Securities from Outperform to Underperform. $11 price target. Estimates were also slashed as Greece and other issues should continue to hang over the industry, JMP said. Myriad Genetics (MYGN) was upgraded at Leerink Swann from Market Perform to Outperform. Reimbursement and IP fears appear overdone, Leerink Swann said.